Dr Joel Bernstein to remain at Winston Pharmaceuticals
This article was originally published in Scrip
Executive Summary
Winston Pharmaceuticals (US) has announced that Dr Joel Bernstein, founder of the company's wholly owned subsidiary Winston Laboratories, has rescinded his resignation as president and chief executive officer and will now continue to serve in the positions for the duration of the term set forth in his employment agreement. Dr Jeffrey Bernstein, who had previously been announced by the company's board of directors as a successor to Dr Joel Bernstein effective September 22nd (scripnews.com, July 30th, 2009), has withdrawn as a candidate for the positions. Winston's board reconfirmed that Robert Yolles, a member of the company's board since 2008, will succeed Dr Joel Bernstein as chairman on September 22nd.
You may also be interested in...
MoCRA Stakeholders Reminded Registration Enforcement Begins 1 July: ‘Do Not Delay!’
The Independent Beauty Association urged stakeholders at its Cosmetic Convergence Symposium to take action to ensure they are meeting requirements of the Modernization of Cosmetics Regulation Act come 1 July, when FDA’s enforcement of the facility and product registration deadline begins. Presenters offered tips from companies that have already completed the process.
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.